Abstract: Genomic and cDNA sequences coding for a protein having substantially the same biological activity as human protein C are disclosed. Recombinant plasmids and bacteriophage transfer vectors incorporating these sequences are also disclosed.

Abstract: The invention provides .alpha.-1-antichymotrypsin and protein preparations comprising human .alpha.-1-antichymotrypsin produced by E. coli cells transformed with a DNA sequence encoding human .alpha.-1-antichymotrypsin. The invention also provides methods for producing .alpha.-1-antichymotrypsin. The invention further provides analogues of .alpha.-1-antichymotrypsin that exhibit antichymotrypsin, anti-trypsin and anti-thrombin activity and methods of producing the analogues.

Abstract: The invention provides .alpha.-1-antichymotrypsin and protein preparations comprising human .alpha.-1-antichymotrypsin produced by E. coli cells transformed with a DNA sequence encoding human .alpha.-1-antichymotrypsin. The invention also provides methods for producing .alpha.-1-antichymotrypsin. The invention further provides analogues of .alpha.-1-antichymotrypsin that exhibit antichymotrypsin, anti-trypsin and anti-thrombin activity and methods of producing the analogues.

Abstract: The present invention provides the isolated DNA sequence encoding the .alpha.B dimer subunit of the lysine-sensitive aspartokinase II isozyme from the thermophilic methylotrophic Bacillus sp. MGA3.

Abstract: Fragments of the factor VIII:C polypeptide have been discovered which exhibit highly specific factor VIII activity. Monoclonal antibodies to the polypeptide fragments and methods for the isolation and purification of said fragments are also disclosed.

Abstract: The invention relates to a protein stabilizing sequence particularly useful for stabilization of proteolytically sensitive proteins. The sequence includes a relatively small number of amino acids that may be expressed fused with a proteolytically sensitive protein. The most effective stabilization sequences assume .alpha.-helix structures with a hydrophobic face and a positively charged polar face which appear to require proper orientation with respect to each other. Other aspects of the invention include cloning vectors incorporating a gene sequence encoding the stabilization polypeptide and production of stabilized antigenic proteins.

Abstract: A cleavage-resistant plasminogen molecule is provided that is conveniently produced in recombinant cells by expression of a nucleic acid sequence encoding the plasminogen molecule. Preferably the plasminogen is a sequence variant with a modification in its two-chain cleavage site. The plasminogen molecule may be purified, acylated, complexed with acylated or non-acylated fibrinolytic enzymes, and formulated into pharmaceutical compositions for use in thrombolytic therapy.

Abstract: The present invention provides for the purification from native sources or the cloning and expression of a variant form of platelet factor 4 and also provides recombinant DNA vectors and methods for the expression and recovery of the platelet factor 4 variant. Also provided are compositions and methods for modulating immune responses in mammals comprising immunomodulating effective amounts of platelet factor 4 variant.

Abstract: DNA having genetic information of a human plasma-type glutathione peroxidase h-p.multidot.GSHPx was identified and disclosed. The enzyme, h-p.multidot.GSHPx, is produced by the expression of said DNA genetic information by a transformant holding a vector into which said DNA is incorporated. The DNA and the transformant ensures efficient production of human plasma type h-p.multidot.GSHPx. The enzyme exhibits lipid peroxide extinction activity, and is considered to be useful for the treatment or the cure or the prevention of these diseases.

Abstract: Fabry disease results from an X-linked deficiency in the enzyme .alpha.-galactosidase A. The present invention is directed to recombinant human .alpha.-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of .alpha.-galactosidase A are also provided.

Abstract: New fragments of the Factor VIII procoagulant protein (Factor VIIIC) are disclosed. These fragments have an Mr value of 88,000 d or 49,000 d or extend from amino acid residues 1974 to 2332 or 2052 to 2332. These fragments have use in the treatment of patients who have developed antibodies which inhibit Factor VIII.

Abstract: Escherichia coli carrying a hybrid plasmid having been constructed by inserting a desired foreign gene into an expression vector so as to permitting expression of said desired foreign gene therein was cultured in a medium containing a sugar component utilizable by the E. coli as a carbon source at a concentration of 0.3% or more so that the expression of said desired foreign gene was suppressed. This E. coli (i.e., transformant) was cultured in the medium in which the sugar concentration was maintained at 0.3% or more in a first process so as to supress the suppression of the foreign gene and to support sufficient cell growth and thereafter at less than 0.3% in a second process to release the suppression of the expression so as to permit effective production of the foreign gene product, which resulted in high concentration of the foreign gene product in the final culture.

Abstract: This invention relates to a method of isolating deletion mutants of Vibrio cholerae, wherein the deletion is predetermined by digestion with restriction endonucleases of known specificity. The deletions are inserted into the Vibrio cholerae chromosome by in vivo recombination between a plasmid carrying the desired deletion, with adjacent flanking sequences, and the Vibrio cholerae chromosome. The invention includes the isolation and characterization of a new Vibrio cholerae strain having a deletion in the tox gene, as defined by Acc I, Xba I, Cla I and/or Hind III restriction endonuclease sites.

Abstract: Genomic and cDNA sequences coding for a protein having substantially the same biological activity as human protein C are disclosed. Recombinant plasmids and bacteriophage transfer vectors incorporating these sequences are also disclosed.